How To Get A Bill Through Congress: Pediatric Cancer Treatment Advocate Scores 2 Wins, 1 Loss

Nancy Goodman, founder of Kids v Cancer, got two bills through Congress via PDUFA riders but struck out with Give Kids a Chance Act, which did not make it into the omnibus government funding legislation. She hopes to prevail next year.

pediatric cancer
Bill authorizing FDA to require pediatric studies of investigational cancer drug combinations is left out of omnibus funding package • Source: Shutterstock

Nancy Goodman began a campaign to expand research on cancer treatments for children after her son died of a rare form of pediatric brain cancer at the age of 10. In the last decade, she has helped write three bills, two of which were enacted into law as part of prescription drug user fee act (PDUFA) reauthorization legislation. The most recent measure, Give Kids a Chance Act, drafted as a rider to PDUFA VII, passed the House but was excluded from the Senate reauthorization bill and did not make it into the final government funding package.

The Give Kids a Chance Act would have amended the Food, Drug, and Cosmetic Act to give the Food and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pink Sheet Perspectives

Nancy Tests Tableau for Bridget

This is a short description.

Navigating The EU's Revised Clinical Trial Disclosure Rules

 
• By 

The European Medicines Agency is preparing to roll out simplified transparency rules for its Clinical Trials Information System in mid-2024. This article looks at what will change and the impact on the thousands of trials that are already in the system.

EU’s Innovative Drug Approval Tally Shows Sharp Decline

 
• By 

The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.

As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

 

Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By 

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.